Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Majictraderon Mar 19, 2020 9:32pm

100 Views

Post# 30828888

RE:RE:RE:Guesstimate for Q4 Results Next Week

It made sense for them to buy Cipher as well. But I am sure Bausch won't allow them because of Trulance. Same issue Kinght buying it. I still hope Bausch buys Cipher. They dont have to give cash out to reduce debt until 2022. So can meet it all via cash generated. Or atleast settles it amically so Cipher can look for other great speciality products with Galephar.

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions